Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AGI-6780 |
Synonyms | |
Therapy Description |
AGI-6780 inhibits mutant IDH2, potentially resulting in increased differentiation and decreased growth of cancer cells harboring IDH2 mutations (PMID: 23558173, PMID: 28986582, PMID: 30455381). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGI-6780 | AGI6780 | IDH2 Inhibitor 5 | AGI-6780 inhibits mutant IDH2, potentially resulting in increased differentiation and decreased growth of cancer cells harboring IDH2 mutations (PMID: 23558173, PMID: 28986582, PMID: 30455381). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH2 R140Q | acute myeloid leukemia | sensitive | AGI-6780 | Preclinical | Actionable | In a preclinical study, treatment with AGI-6780 resulted in the differentiation of erythroleukemia and AML cell lines expressing IDH2 R140Q (PMID: 23558173). | 23558173 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|